Skip to main content
Home > BioCentury on BioBusiness > Cover Story

Chronological Index of : Cover Story

 Current Issue
  • Volatile, not futile

    Biotech turned red in 3Q15 but bankers, buysiders say it's the lone growth sector

    Pricing is on the radar of generalist investors, and likely will remain an issue through next year's presidential election in the U.S.

    Published on 10/5/2015
  • Drawn and quartered

    Biotech winners, losers in 3Q15

    3Q15 saw every biotech market cap band post big losses, although a few winners emerged in each group.

    Published on 10/5/2015
  • Figure: London vs. Europe

    Drawn and quartered London vs. Europe Despite massive declines in the U.S.-centric biotech indices, the BioCentury Europe declined just 1% in 3Q15, and the BioCentury London dropped just 0.2%. The market cap-…

    Published on 10/5/2015
  • Figure: Price-to-earnings: BT vs. RX

    Drawn and quartered Price-to-earnings: BT vs. RX The average P/E for big biotechs ended the quarter at 20.2, the lowest level since 4Q12, when the multiple was 18.4. The group's P/E is down 23% from 2Q15 and 8% …

    Published on 10/5/2015
  • Figure: Results by market cap

    Drawn and quartered Results by market cap All market cap segments ended the quarter down by more than 15%, led by a 22.2% decline in the group of companies valued at $500-$999 million. The decline across the board…

    Published on 10/5/2015
  • Table: 3Q approvals

    Drawn and quartered 3Q approvals Selected third quarter approvals. Company Approval AbbVie Inc. (NYSE:ABBV) FDA approves Technivie ombitasvir/paritaprevir/ritonavir in combination with ribavirin to treat non-…

    Published on 10/5/2015
  • Table: Index performance

    Drawn and quartered Index performance Index 3Q15 YTD BioCentury London 0% 6% BioCentury Europe -1% 18% S&P 500 -7% -7% NASDAQ Composite -7% -2% DJIA -8% -9% NYSE Arca Pharmaceutical -9% -2% …

    Published on 10/5/2015
  • Table: Restructuring watch

    Drawn and quartered Restructuring watch At least one company reported workforce reductions in the third quarter compared to at least eight in the same period last year. This is the smallest number since 4Q14 and …

    Published on 10/5/2015
  • Table: 4Q15 milestones

    Event planner 4Q15 milestones Selected products with Phase III or regulatory milestones expected in 4Q15. Source: BCIQ: BioCentury Online Intelligence Company Product Indication Event Milestone AbbVie Inc.…

    Published on 10/5/2015
  • Event planner

    Investors' top names, milestones and meetings in 4Q15

    Buysiders interested in putting money to work in 4Q15 have a full plate of late-stage milestones to look forward to.

    Published on 10/5/2015
  • Figure: Biotech fund flows

    Volatile, not futile Biotech fund flows Despite outflows in the past two months, biotech funds saw net inflows of $503.3 million during 3Q and $6.3 billion for the first three quarters of 2015. The September fund …

    Published on 10/5/2015
  • Figure: Cranking the volume

    Volatile, not futile Cranking the volume Since Hillary Clinton's "price gouging" tweet on Sept. 21, the iShares NASDAQ Biotechnology ETF (IBB) is down 12%, with average daily trading volume of 5.9 million shares.…

    Published on 10/5/2015
  • Table: Follow-on performance

    Volatile, not futile Follow-on performance Forty-six biotechs raised $5.4 billion, bringing the year-to-date tally to $24.5 billion, more than any amount raised in a full year since BioCentury started tracking …

    Published on 10/5/2015
  • Table: IPO performance

    Volatile, not futile IPO performance In 3Q15, 15 biotechs raised $1.8 billion in IPOs, down from 30 for $3 billion in 3Q14. The last time 15 IPOs or fewer were completed in a quarter was in 1Q13, when seven …

    Published on 10/5/2015
  • Table: IPO queue

    Volatile, not futile IPO queue Nineteen companies have announced plans to go public since the start of 3Q15, bringing the IPO queue to at least 28. Unless noted, companies are seeking to list on NASDAQ. Most …

    Published on 10/5/2015
  • Goodwill hunting

    Commentary: Individual companies, not BIO, PhRMA, must address Turing outcry

    Commentary: Don't count on BIO or PhRMA to beat down the Turing outcry; goodwill with the public will be built one company at a time.

    Published on 9/28/2015
  • Table: A brief history

    Goodwill hunting A brief history Hillary Clinton's plan for lowering prescription drug costs aggregates ideas that have been staples of Democratic drug cost-containment legislation for over a decade. 
 Sources: …

    Published on 9/28/2015
  • Table: Cancer exclusions

    England's cancer problem Cancer exclusions Cancer medicines dropped by the Cancer Drugs Fund. Removed indications include those that have not been appraised by NICE as well as those rejected by the agency. (A) The…

    Published on 9/21/2015
  • England's cancer problem

    Why cancer drug access still in doubt in NHS England

    Cuts by NHS England's Cancer Drugs Fund are limiting patient options, and a system to replace it may not pay for drugs with proven efficacy.

    Published on 9/21/2015
  • Parting ways

    Innovators and biosimilars companies are turning to inter partes review for freedom to operate

    While trade associations are fighting for exemption from inter partes review, innovators are using the method to attack competitors' patents.

    Published on 9/14/2015
  • Box: Enlisting patients

    IPR battles Enlisting patients BIO has placed obtaining an inter partes review exemption for drug patents on the top of its legislative agenda, deploying CEOs to speak to members of Congress about patent reform …

    Published on 9/14/2015
  • Figure: Short skeptics

    IPR battles Short skeptics Compared with each company's historical averages, short interest has increased more than 20% in only three companies hedge fund manager Kyle Bass has targeted with petitions for inter …

    Published on 9/14/2015
  • Table: IPR tally

    IPR battles IPR tally Hedge funds have filed petitions for inter partes reviews (IPRs) of patents covering at least 16 drugs marketed in the U.S. by 14 public companies. Six declined in market value during the …

    Published on 9/14/2015
  • IPR battles

    Who's winning and who's losing at IPR so far

    So far, inter partes review hasn't been a drug patent killer, but BIO and PhRMA say it is a threat that must be slain.

    Published on 9/14/2015
  • Changing the subject

    23rd BioCentury Back to School Issue: Let patients show the way in drug development

    As 'value' becomes the rallying cry of payers, the 23rd Back to School essay says industry must help patients show the way throughout the product life cycle.

    Published on 9/7/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993